Cingulate Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CING research report →
Range $9 – $9
Price Chart
About the company
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine).
- CEO
- Shane J. Schaffer
- IPO
- 2021
- Employees
- 14
- HQ
- Kansas City, KS, US
Get TickerSpark's AI analysis on CING
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $67.48M
- P/E
- -1.04
- Fwd P/E
- 10.49
- PEG
- 0.61
- P/S
- 0.00
- P/B
- 1.38
- EV/EBITDA
- -2.15
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -177.95%
- ROIC
- -120.45%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-19,938,108
- Net Income
- $-22,449,911-35.6%
- EPS
- $-4.13+59.5%
- OCF Growth
- +6.5%
- FCF Growth
- +6.7%
- 52W High
- $11.89
- 52W Low
- $3.16
- 50D MA
- $4.82
- 200D MA
- $5.36
- Beta
- -0.89
- RSI (14)
- 59
- Avg Volume
- 167.21K
No earnings-call transcripts are available for CING yet.
- Free Float
- 83.5%
- Shares Outstanding
- 14.96M
- Float Shares
- 12.49M
of shares held by institutions
38 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 570.87K | 0 |
| Raymond James Financial Inc | 214.90K | ▲ 48.00K |
| Renaissance Technologies LLC | 186.38K | ▲ 58.88K |
| Marshall Wace, Llp | 160.38K | ▲ 160.38K |
| Kestra Advisory Services, LLC | 156.50K | ▲ 5.00K |
| Geode Capital Management, LLC | 152.82K | ▲ 8.18K |
| Vanguard Group Inc | 151.43K | ▲ 77.64K |
| Bolton Securities Corporation | 139.00K | 0 |
| Chicago Partners Investment Group LLC | 110.74K | ▼ 77.69K |
| North Star Investment Management Corp. | 100.00K | ▲ 100.00K |
| Vanguard Fiduciary Trust Co | 88.83K | ▲ 9.67K |
| Simplex Trading, LLC | 70.98K | ▲ 70.98K |
Held by 23 ETFs
Biggest fund positions in CING by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | Silva Raul R. | other | 4,293 |
| Jul 16, 26 | Schaffer Shane J. | other | 197,650 |
| Jul 16, 26 | Schaffer Shane J. | other | 97,350 |
| Jul 16, 26 | Downey Bryan Wade | other | 67,000 |
| Jul 16, 26 | Downey Bryan Wade | other | 33,000 |
| Jul 16, 26 | Lawrence Bryan Jay | other | 20,000 |
| Jul 16, 26 | Brams Matthew | other | 53,600 |
| Jul 16, 26 | Brams Matthew | other | 26,400 |
| Jul 16, 26 | Hargroves Thomas Jeffrey | other | 20,000 |
| Jul 16, 26 | Callahan Jennifer L. | other | 40,200 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CING coverage
Recent articles, reports, and earnings notes.
No research on CING yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CING report →Cingulate Announces U.S. Patent Issuance for CTx-2103, Further Validating PTR™ Technology Platform
globenewswire.com · Nov 19
Cingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission
globenewswire.com · Nov 13
Shane Schaffer, Cingulate Chairman and CEO, Provides Update on CTx-1301 in Interview with Innovators with Jane King
globenewswire.com · Nov 10
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
globenewswire.com · Sep 17
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
globenewswire.com · Aug 13
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301's Differentiated Pharmacokinetic Profile
globenewswire.com · Aug 11
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
globenewswire.com · Jul 30
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
globenewswire.com · Jul 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.